Breaking News, Collaborations & Alliances

Polaris Group Acquires Genovior Biotech

Expands product pipeline into the highly promising realm of peptide drugs.

Polaris Group, a biopharmaceutical company, has acquired Genovior Biotech, a contract development and manufacturing organization (CDMO). Also, Steve Hsu, chairman of Genovior, has been appointed CEO of Polaris. The acquisition expands Polaris Group’s product pipeline beyond its novel cancer metabolism therapy into the realm of peptide drugs, such as the widely recognized Semaglutide-related products. These two highly prospective product lines will support Polaris Group’s future gr...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters